Orphan Drugs Market Access and Regulatory Affairs


Many blockbuster drugs will lose their exclusivity in the next five years. Therefore, the current economic situation has shifted the focus of many pharmaceutical companies from essential medicines to orphan drugs.

> Hear about the Latest Trends and Developments in Orphan Drugs Legislation
> Learn about Early Access to Orphan Drugs for Patients with Unmet Medical Need
> Discuss Orphan-Drug Designations and Marketing Approvals in the New Millennium and FDA and EMA Experiences
> Explore the Regulatory Landscape for Orphan Drug Development in order to Anticipate Future Changes

> Early access to Orphan Drugs for patients with unmet medical need
> Patient Centered Approach Seen by Patients
> Orphan Drug Designations and Marketing Approvals in the New Millennium
> Road from R&D to Market and more

Visitors

Anyone involved with Orphan Drugs, Drug Development and

Exhibitors

We want to innovate, grow professionally, evaluate the practices that work and take in recent case studies from your field? Then you are the right person to join other professionals at exclusive webinars by Kakushin.

Go to event website